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The concept of pharmacovigilance and the need for the monitoring 
of medicine-related harms has been in existence for more than 
150  years.[1] The thalidomide limb malformation disaster in the 
1960s prompted the development of a number of spontaneous 
adverse event reporting systems and legislation in Europe and 
elsewhere, in order to regulate and monitor medicine safety.
The simplest form of pharmacovigilance involves spontaneous 
reporting systems that collect information on suspected adverse 
effects of drugs post marketing.[2] The primary aim of a spontaneous 
reporting system is to detect early signals of new, serious or rare 
adverse drug reactions (ADRs).[2] Pharmacovigilance is increasingly 
recognised and promoted as an important component of public 
health systems in order to support safe, rational and cost-effective use 
of medicines and to minimise any related harms.[3]
In Western Cape Province, South Africa (SA), the Western 
Cape Department of Health, in collaboration with the Medicines 
Information Centre (MIC) in the Division of Clinical Pharmacology 
at the University of Cape Town (UCT), introduced a targeted 
spontaneous reporting system for suspected ADRs to antiretrovirals 
in 2005, to inform the antiretroviral treatment programme 
regarding the safety of medicines used in the programme.[4] This 
programmatic pharmacovigilance system, which also included 
tuberculosis treatment from 2012, has been described previously. [4] 
In 2014, this service was further expanded to provide a broader 
pharmacovigilance service that solicits reports of suspected ADRs to 
all medicines encountered in Western Cape public sector healthcare 
facilities. The goals of this reporting system are to identify possible 
signals of previously undocumented rare ADRs, or increased severity 
of known ADRs, and to instil a culture of drug safety awareness 
among healthcare workers (HCWs). The programme encourages 
HCWs to report all suspected ADRs, especially serious reactions that 
are potentially life-threatening, cause hospitalisation or extended 
hospital stay, or permanent disability, or require the offending drug 
to be stopped. In addition, any deaths suspected to be associated with 
an ADR and any exposure to a known teratogen are also requested 
to be reported. Quarterly and annual reports are shared with HCWs, 
including preventability issues and drug safety learning points.
Objectives
We describe reports to the Western Cape pharmacovigilance service 
over a 4-year period between January 2015 and December 2018, 
excluding suspected ADRs to HIV and TB medications, which 
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Background. There are limited data in South Africa (SA) on adverse drug reaction (ADR) patterns and common causative medicines, 
outside of HIV and tuberculosis treatment programmes. In SA, Western Cape Province has a pharmacovigilance programme that collects 
spontaneous reports of suspected ADRs from public sector healthcare facilities.
Objectives. To describe reports received by the pharmacovigilance programme over a 4-year period (excluding those ascribed to medicines 
used to treat HIV and tuberculosis), as well as challenges faced in the implementation of such a system.
Methods. Reports of suspected ADRs and deaths possibly related to ADRs received between January 2015 and December 2018 were 
reviewed. Causality was assessed by a pharmacist, with multidisciplinary team involvement for all deaths and complicated cases. Causality 
was categorised according to the World Health Organization-Uppsala Monitoring Centre system. Preventability was assessed using 
Schumock and Thornton criteria. Observations on preventability and challenges faced in the operation of a spontaneous reporting system 
were also noted.
Results. We received 5 346 reports containing 6 023 suspected ADRs. There were 5 486 ADRs confirmed after causality assessment, in 5 103 
reports. Cough, angio-oedema, movement disorders and uterine bleeding disorders were the most common ADRs. Enalapril, etonogestrel, 
amlodipine and hydrochlorothiazide were the most commonly implicated drugs. Seven deaths were reported; 3 of these reports of deaths 
had confirmed ADRs, and these ADRs were assessed as contributing to the deaths. Approximately 3.8% of commonly reported ADRs were 
preventable.
Conclusions. Enalapril and etonogestrel were responsible for a significant proportion of ADRs reported to this provincial programme. 
Future work should include quantification of preventability aspects to better inform gaps in healthcare worker knowledge that can be 
addressed in order to improve patient care.
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are described elsewhere.[4] We also describe lessons learned and 
challenges faced in the implementation of an ADR reporting system 
in a public health system environment.
Methods
ADR reports were submitted to the MIC by HCWs using a 
standardised reporting form, which is also used by the national 
medicines regulatory authority. Reports could be submitted by email 
or fax, and since June 2016 reports could be submitted electronically 
via Sinjani, which is the reporting portal for public sector facilities in 
the Western Cape. Reports are stored in a registry maintained by the 
MIC. Initial assessment of the reports is performed by a pharmacist, 
who contacts the reporter for additional information should it be 
required for assessment of causality and preventability.
We reviewed reports received between January 2015 and 
December 2018. An information pharmacist performed causality 
assessment of suspected ADRs. A clinical pharmacologist and/or 
a doctor was included in causality assessment for complex cases 
and deaths. We used the World Health Organization-Uppsala 
Monitoring Centre (WHO-UMC) system[5] for assessing causality, 
which classifies ADRs as definite, probable, possible, unlikely or 
unassessable.
‘Confirmed ADRs’ were those categorised as definite, possible 
or probable using the WHO-UMC system.[5] For all deaths, the 
contribution of any confirmed ADR to the death was assessed, and 
the ADR was classified as a major contributor, contributor or non-
contributor to the patient’s death.
MedDRA terminology was used to describe the ADRs. Individual 
ADRs were also grouped under a higher-level term describing an 
ADR category, as set out in Table 1. MedDRA is a hierarchical 
medical terminology dictionary used by pharmaceutical industry 
regulators for recording of drug safety data, among other things.[6]
Schumock and Thornton criteria[7] were used to assess 
preventability. The ADR was categorised as preventable if any of the 
following criteria were met: drug prescribed inappropriate, dose/
route/frequency inappropriate, laboratory monitoring not performed 
as required, history of a previous reaction to the drug, drug 
interaction, toxic serum drug level, and poor compliance.
The MIC maintains a repository of ADRs reported to the Western 
Cape pharmacovigilance system with UCT Human Research Ethics 
Committee (HREC) approval (ref. no. R040/2016). This sub-study 
also has UCT HREC approval (ref. no. 541/2019).
Results
From 1 January 2015 to 31 December 2018, we received 5 346 reports 
detailing 6 023 suspected ADRs. After causality assessment, there 
were 5 486 confirmed ADRS, which were detailed in 5 103 reports. 
Patient characteristics for these 5 103 reports, as well as the cadre of 
HCW submitting the report, are described in Table 2.
Causality according to the WHO-UMC system was assessed as 
follows: certain n=142 (n=2 with multiple suspect drugs), probable 
n=1 906 (n=81 with multiple suspect drugs), and possible n=3 438 
(n=84 with multiple suspect drugs). Two suspected ADRs were 
assessed as unlikely to be an ADR, and 535 ADRs were unassessable.
The 10 most commonly reported ADR categories as well as the 
top implicated drug are reflected in Fig. 1. The 10 most commonly 
implicated drugs and the associated ADR categories are presented 
in Table 3.
Seventy-six percent of ADRs (4 132/5 435) were in the top 10 
ADR categories. In the top 10 ADR categories, 159 ADRs were 
Table 1. ADR categories and terms
ADR category ADR terms
Rashes, eruptions and exanthems NEC Rash NOS, Rash erythematous, Rash papular, Rash maculo-papular, Rash macular, 
Rash morbilliform, Rash generalised
Muscle disorders Muscle cramps, Myalgia, Muscle rupture, Rigors
General system disorders NEC Oedema, Condition aggravated
Nausea and vomiting symptoms Nausea, Nausea and vomiting, Nausea, vomiting and diarrhoea
Neurological disorders NEC Dizziness, Ataxia, Tics
Headaches NEC Headache
Menstrual cycle and uterine bleeding disorders Menorrhagia, Metrorrhagia, Dysfunctional uterine bleeding, Menstruation irregular, 
Amenorrhoea, Dysmenorrhoea
Movement disorders Dystonia, Extrapyramidal disorder NOS, Tremor, Parkinsonism, Akathisia, Tardive 
dyskinesia, Neuroleptic malignant syndrome, Oculogyric crisis, Torticollis, Rabbit 
syndrome
Angio-oedemas Angio-oedema, Swollen tongue, Lip swelling
Coughing and associated symptoms Cough
ADR = adverse drug reaction; NEC = not elsewhere classified; NOS = no other symptoms.
Table 2. Patient and reporter characteristics
n (%)
Patient characteristics (N=5 103)
Sex
Female 3 829 (75.0)
Male 1 226 (24.0)
Unknown 48 (0.9)
Age
Adults and adolescents >12 years 4 793 (93.9)
≤12 years 61 (1.2)
Unknown 249 (4.9)
Number of confirmed ADRs in the report
1 4 827 (94.6)
2 233 (4.6)
3 - 5 43 (0.8)
Reporter characteristics
Doctor 2 621 (51.4)




ADRs = adverse drug reactions.
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assessed as preventable (159/4 132; 3.8%). Some common themes in 
terms of preventability were observed. These included: (i) recurrent 
episodes of persistent cough due to rechallenges of enalapril (in 
some cases this was mismanaged by switching to a different brand 
of enalapril); and (ii) recurrent episodes of angio-oedema while 
remaining on enalapril, or due to inadvertent rechallenges. There 
were also 3 reports of menstrual cycle and uterine bleeding disorders 
and 1 of contraceptive failure in patients with etonogestrel implants 
who were on concomitant enzyme-inducing medications (efavirenz, 
phenytoin). These drug interactions may have resulted in decreased 
etonogestrel concentrations, with resultant contraceptive failure.
We received 21 reports of suspected ADRs in pregnant women, 
of which we confirmed 21. There were 3 cases of anaphylaxis due 
to cefazolin, 2 cases of angio-oedema due to enalapril (which is 
also contraindicated in pregnancy, as are all angiotensin-converting 
enzyme (ACE) inhibitors[8]), and 16 cases of inadequate spinal 
anaesthesia for caesarean section using bupivacaine. The cases of 
inadequate spinal anaesthesia despite correct administration pointed 
Rashes, eruptions and exanthems NEC
Muscle disorders
General system disorders NEC
Nausea and vomiting symptoms
Neurological disorders NEC
Headaches NEC
Menstrual cycle and uterine bleeding disorders
Movement disorders (incl. parkinsonism)
Angio-oedemas
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Fig. 1. Top 10 ADR categories and top implicated drug in each category, 2015 - 2018. (ADR = adverse drug reaction; NEC = not elsewhere classified.)
Table 3. Top 10 implicated drugs and most commonly associated ADR categories
Implicated drug Reports, n Top 3 associated ADR categories
Enalapril 2 337 Coughing and associated symptoms (n=1 494; 63%), Angio-oedemas (n=578; 25%), 
Headaches NEC (n=64; 3%)
Etonogestrel 816 Menstrual cycle and uterine bleeding disorders (n=406; 50%), Headaches NEC (n=155; 19%), 
Appetite and general nutritional disorders (n=73; 9%)
Amlodipine 567 General system disorders NEC (n=155; 27%), Coughing and associated symptoms (n=151; 
27%), Angio-oedemas (n=72; 13%)
Hydrochlorothiazide 409 Coughing and associated symptoms (n=189; 46%), Angio-oedemas (n=96; 23%),  
Muscle disorders (n=18; 4%)
Simvastatin 356 Muscle disorders (n=121; 34%), Coughing and associated symptoms (n=79; 22%),  
Angio-oedemas (n=29; 8%)
Risperidone 305 Movement disorders including parkinsonism (n=168; 55%), Breast disorders (n=69; 23%), 
Salivary gland conditions (n=24; 8%)
Atenolol 179 Coughing and associated symptoms (n=58; 32%), Neurological disorders NEC (n=15; 8%), 
Angio-oedemas (n=12; 7%)
Metformin 170 Gastrointestinal motility and defaecation disorders (n=46; 27%), Coughing and associated 
symptoms (n=34; 20%), Nausea and vomiting symptoms (n=20; 12%)
Haloperidol 120 Movement disorders including parkinsonism (n=106; 88%), Breast disorders (n=5; 4%), 
Salivary gland conditions (n=4; 3%)
Sodium valproate 119 Movement disorders including parkinsonism (n=64; 54%), Salivary gland conditions  
(n=19; 16%), Platelet disorders (n=7; 6%) 
ADR = adverse drug reaction; NEC = not elsewhere classified.
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to a possible product quality issue that was referred to the relevant 
authority for further investigation.
Seven reports of deaths in which an ADR was suspected were 
received during the period under review. Four of these deaths were 
unassessable owing to a paucity of clinical information, despite 
repeated attempts to contact the reporters. The details of the 
remaining three deaths were as follows:
A 59-year-old woman with hypertension and breast cancer was 
receiving paclitaxel, dexamethasone, promethazine, cimetidine, 
amlodipine and hydrochlorothiazide. She developed angio-
oedema during a paclitaxel infusion and subsequently died despite 
interventions to intubate and resuscitate. This episode was assessed 
as a certain ADR attributed to paclitaxel and was a major contributor 
to the patient’s death.
An 11-month-old female infant with bilateral pneumonia 
and pulmonary hypertension was being treated with amikacin, 
piperacillin/tazobactam and cloxacillin. She developed acute renal 
failure and subsequently died. It transpired that she had been given 
amikacin 8-hourly instead of once daily. The amikacin level was 
measured and found to be in the toxic range. This death was assessed 
as a probable and preventable ADR that was a major contributor to 
the patient’s death.
A 42-year-old known hypertensive and diabetic patient suffered an 
inferolateral myocardial infarction. He was given 1.5 MU streptokinase 
(no contraindications) as per protocol and subsequently developed 
eight subarachnoid bleeds and died. He also received enoxaparin, 
aspirin, clopidogrel, simvastatin and insulin. The streptokinase was 
assessed as a probable cause of subarachnoid haemorrhage, with 
enoxaparin, aspirin and clopidogrel as other possible contributors. 
Subarachnoid haemorrhage was a major contributor to the patient’s 
death.
Discussion
Over a 4-year period, the MIC (on behalf of the Western Cape 
Province pharmacovigilance programme) received 5 346 reports 
of suspected ADRs, excluding reports where HIV and/or TB 
medications were implicated. Of 6 023 suspected ADRs, 5 486 were 
confirmed on causality assessment, of which 3.8% were assessed as 
preventable. This is low compared with a recent prospective study 
in our setting.[9] The most common ADRs reported were cough, 
angio-oedema, movement disorders and menstrual/uterine bleeding 
disorders, which corresponds to the known ADR profiles of the 
medications in the standardised formularies in SA, which include the 
Essential Medicines List (EML) and the Practical Approach to Care 
Kit (PACK).[10] Three patients died with an ADR considered to have 
contributed directly to the death.
Approximately 41% of all confirmed ADRs were associated with 
the use of enalapril, of which cough and angio-oedema were the 
most common. In 2015, access to the angiotensin receptor blocker 
losartan was expanded to allow medical officers to prescribe it in 
consultation with a specialist, provided an ADR form reporting 
enalapril intolerance was also completed. This policy is likely to have 
contributed to the high proportion of reported ADRs that implicated 
enalapril. Many cases of cough were assessed as preventable due to 
subsequent re-initiation of the offending drug. This re-initiation 
may have been due to insufficient record-keeping. In some cases, 
the cough was mismanaged by switching to a different brand, 
highlighting the need for education of HCWs about the aetiology 
of ACE inhibitor-induced cough. Some cases of angio-oedema were 
categorised as preventable because of repeated episodes in the same 
patient before the offending drug was stopped. These recurrent 
episodes emphasise the importance of questioning patients about 
the occurrence of side-effects at regular intervals, and also of having 
systems in place to alert other HCWs to patients with known allergies 
(e.g. electronic health records, stickers on folders and MedicAlert 
bracelets). These issues were communicated back to HCWs via the 
quarterly and annual reports, and a poster is also being developed 
summarising angio-oedema and its management.
The second most commonly implicated drug was the etonogestrel 
implant. This contraceptive option was introduced into the public 
sector formulary in November 2013 and actively promoted as a 
preferred choice. The large number of ADR reports may suggest 
some patient dissatisfaction with this option, or alternatively 
increased ADR awareness and vigilance on the part of HCWs after 
the introduction of a new medication.
Study limitations and strengths
The main limitation of this study is that ADRs are probably under-
reported, which is a known weakness of all spontaneous reporting 
systems. We cannot calculate the incidence or prevalence of ADRs or 
identify risk factors, as we do not have denominator data.[3] Causality 
assessment was often challenging owing to provision of insufficient 
information. Another limitation is that repeated entries for individual 
patients are not linked in the database, so there may be repeated ADR 
reports submitted for some individuals. A strength of this study is the 
standardised, widely used causality assessment by a pharmacist, with 
multidisciplinary team involvement in assessment of more complex 
cases and all deaths. Future research could incorporate quantitative 
measurement of preventable ADRs in order to better identify gaps in 
HCW knowledge that can be addressed.
In an effort to make reporting of ADRs easier, an internet/intranet-
based option was added to the paper-based reporting form in the 
Western Cape’s electronic health information system, Sinjani. The 
actual design and building of the ADR module was challenging in 
terms of communicating requirements and desired functionality 
to the IT developers. Once this module was operational, it was 
discovered that many reports were being captured retrospectively 
by non-medical data capturers, which often resulted in incorrectly 
entered information due to factors such as illegible handwriting and 
insufficient medical and pharmaceutical knowledge. Extra follow-
up was therefore needed by the pharmacist assessing causality. In 
addition, it was also often difficult to trace the original reporter. 
A number of communications had to be sent out requesting that 
only HCWs personally submit reports, but with time this has 
resolved, and the Sinjani option is a useful addition to methods 
of reporting. Another challenge has been difficulty in assessing 
causality due to provision of insufficient information. In this cohort, 
535/6 023 suspected ADRs (8.9%) were unassessable according to 
WHO criteria. Examples of missing information include no start/
stop dates of medicines; lack of information on dose, frequency of 
administration and duration of therapy for each medicine; lack of 
information on date of onset, duration, resolution and outcomes of 
reaction; insufficient supporting information on the type of reaction 
(e.g. renal impairment described but without any laboratory results); 
and only listing the suspected drug and not concomitant medications. 
This problem can be overcome to some extent by having mandatory 
fields in the electronic form, but it is still an issue with the paper-
based forms.
Conclusions
Enalapril followed by etonogestrel were the most commonly 
implicated medicines and responsible for a significant proportion 
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of ADRs reported to this provincial pharmacovigilance programme. 
Many enalapril ADRs could have been prevented by appropriate 
attention to the patient’s history and accessible drug information.
In addition, the programme highlighted product quality issues that 
resulted in treatment failure in some patients.
This spontaneous voluntary reporting system in a public health 
sector environment provides useful information regarding the types 
of ADRs experienced and underscores the importance of accessible 
and visible patient records. It highlights medicine-related gaps in 
knowledge of healthcare workers. Guidance on diagnosis, prevention 
and management of these ADRs should be prioritised for inclusion in 
HCW training in order to improve patient care. It may also reinforce 
a culture of drug safety awareness and the avoidance of medicine-
related harms.
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